TEXAS CHILDREN'S HOSPITAL
EVIDENCE-BASED OUTCOMES CENTER
DIABETIC KETOACIDOSIS (DKA) CLINICAL GUIDELINE
Evidence-Based Guideline

Definition: Diabetic ketoacidosis (DKA) is a decrease in effective circulating insulin associated with increases in counter regulatory hormones (e.g., glucagon, catecholamines, cortisol, and growth hormone). Hyperglycemia and acidosis result in osmotic diuresis, dehydration, and obligate loss of electrolytes. [1]

Biochemical Criteria: blood glucose >200 mg/dL; venous pH <7.3 and/or bicarbonate <15 mmol/L with ketones in blood or urine. [1]

Pathophysiology: [2] Insulin deficiency is the initial primary event in progressive β-cell failure, its exogenous omission in a patient with established disease, or its relative ineffectiveness when insulin action is provoked by physiological stress (e.g., sepsis) and in the context of counterregulatory hormone excess. These hormonal changes augment glucose production from glycogenolysis and gluconeogenesis while limiting glucose utilization. This process results in hyperglycemia (>11 mmol/L, approximately 200 mg/dL), osmotic diuresis, electrolyte loss, dehydration, decreased glomerular filtration, and hyperosmolarity. Simultaneously, lipolysis provides increased free fatty acids. The oxidation of free fatty acids facilitates gluconeogenesis and generates acetoacetic and β-hydroxybutyric acids (ketones) that overwhelm buffering capacity, resulting in metabolic acidosis (pH 7.3). This is compounded by lactic acidosis from poor tissue perfusion. Progressive dehydration, hyperosmolarity, acidosis, and electrolyte disturbances exaggerate stress hormone secretion and establish a self-perpetuating cycle of progressive metabolic decompensation.

Epidemiology: DKA occurs in 26% of children with new onset type 1 diabetes (T1DM). [3] DKA is the leading cause of morbidity and mortality in children with diabetes. [4,5] Mortality rates are less than 1% with the majority (62-87%) of these caused by cerebral edema.

Risk Factors for Cerebral Edema (CE): [6-11]
- Age <5 years
- New onset diabetes
- High initial serum urea
- Low initial partial pressure of **arterial** carbon dioxide
- Rapid administration of hypotonic fluids
- Failure of corrected serum sodium to rise during treatment
- Treatment with bicarbonate (HCO_3)

Etiology: DKA is characterized by the triad of hyperglycemia, increased ketone concentration in the blood and/or urine, and metabolic acidosis. The metabolic derangements in DKA result from the combination of absolute or relative insulin deficiency (levels insufficient to suppress gluconeogenesis and ketone production) and elevation of counterregulatory hormones (glucagon, epinephrine, norepinephrine, cortisol, and growth hormone).

DKA can occur at any age in people with type 1 diabetes, type 2 diabetes, or any other type of diabetes. However, DKA is more common in young people with type 1 diabetes. Precursors to DKA, may include any illness; however, the most frequent reason is infection, particularly urinary tract infections and pneumonia, and the omission of insulin therapy. In recent years, sodium–glucose cotransporter 2 (SGLT2) inhibitors have been found to increase the risk of DKA. [12]

Inclusion Criteria
- Age: 6 months to 21 years
- Clinical findings of DKA

Exclusion Criteria
- 0 to 5 months of age
- Hyperglycemia without acidosis

Differential Diagnosis
Sepsis
Stress-induced or steroid-related hyperglycemia
Inborn errors of metabolism
Hyperosmolar coma

Diagnostic Evaluation
History: Assess for
- Diabetes
- Polyuria, polydipsia, polyphagia
- Estimated weight loss
- Abdominal pain, vomiting
- Concurrent illness or infections
- Kussmaul respiration (rapid and/or deep sighing)
- Inadequate insulin therapy (e.g., non-adherence, inappropriate dosing)
- Altered sensorium˜, headache
- Steroid use

˜ The recording of conscious level is a vital assessment in the management of children with DKA as CE is rare but potentially devastating. [1]

Physical Examination
Degree of acidosis (mild, moderate, severe) is an important marker for determining the severity of DKA and is a risk factor for CE. Clinical assessment of dehydration can be imprecise. It's important to treat children with DKA based on a moderate level of dehydration.
- Airway, breathing, circulation
- Weight (actual), height, m^2
- Age <5 years
- Blood pressure, heart rate, respiratory rate, temperature
- Fruity breath
- Kussmaul respiration (rapid and/or deep sighing)
- Neurological status† (e.g., level of consciousness, fundal exam, pupils, Babinski reflex)

Degree of Acidosis:
- Mild/Moderate- venous pH 7.0-7.30
- Severe- venous pH <7.0

Modified Glasgow Coma Score (GCS) for Infants , Children, and Adults

	Adult	Child	Infant	Score
Eye opening	Spontaneous	Spontaneous	Spontaneous	4
	To speech	To speech	To speech	3
	To pain	To pain	To pain	2
	None	None	None	1
Best verbal response	Oriented	Oriented, appropriate	Coos and babbles	5
	Confused	Confused	Irritable cries	4
	Inappropriate words	Inappropriate words	Cries to pain	3
	Incomprehensible sounds	Incomprehensible sounds	Moans to pain	2
	None	None	None	1
Best motor response	Obeys	Obeys commands	Moves spontaneously and purposefully	6
	Localizes	Localizes painful stimulus	Withdraws to touch	5
	Withdraws	Withdraws in response to pain	Withdraws in response to pain	4
	Abnormal flexion	Flexion in response to pain	Abnormal flexion posture to pain	3
	Extensor response	Extension in response to pain	Abnormal extension posture to pain	2
	None	None	None	1

Laboratory Tests

Obtain immediately by bedside meter:

- Blood glucose
- β-hydroxybutyrate

Additional tests:

- K, HCO_3, Cl, glucose
- BUN, Cr
- β-hydroxybutyrate
- Blood gas

For new onset diabetes:

- Diabetes panel
- Celiac panel
- Thyroglobulin antibodies panel

Critical Points of Evidence*

TCH Evidence-Based Recommendations

Evidence Supports

- The use of potassium values from the venous blood gas to guide decisions regarding potassium supplementation. (13) – Strong recommendation, moderate quality evidence
- The use of 0.9% sodium chloride solution (normal saline) for rehydration in children age five years or older. Give one 20 mL/kg normal saline bolus, assess need for a second 20 mL/kg bolus. – Strong recommendation, moderate quality evidence
  Remarks: In the studies reviewed, there appeared to be no clinically significant differences between types of fluids nor rate.
- Subsequent fluid management should amount to 2500 mL per meter squared per day (subtract boluses; do not subtract boluses if rate dips below maintenance). The administration of lactated ringers as a maintenance fluid to minimize or decrease severity and/or risk of hyperchloremic acidosis (Cl level > 110 mEq/L) – Strong recommendation, moderate quality evidence. (14-22; 36-40)
- The use of intravenous insulin to correct diabetic ketoacidosis when the patient has a pH <7.3. (23-26) – Strong recommendation, very low quality evidence
  Remarks: In light of the equivocal evidence, the team decided to standardize and use IV insulin as the preferred approach. In circumstances where continuous IV administration is not possible for patients with uncomplicated DKA, serial subcutaneous insulin administration every 3 hours are safe and may be as effective as IV regular insulin infusion, but ideally should not be used in patients whose peripheral circulation is impaired.
- The administration of mannitol or hypertonic saline (3%) in pediatric patients with diabetic ketoacidosis and cerebral edema. (27) – Strong recommendation, very low quality evidence
- The use of clinical judgment to determine if treatment is needed for cerebral edema. (28) – Strong recommendation, very low quality evidence
  Remarks: Do NOT delay hyperosmolar treatment for CT in a patient with suspected cerebral edema. Consider CT in patients with altered mental status who have been given hyperosmolar treatment, or in whom the neurological exam has not improved with hyperosmolar therapy, or in patients with suspected alternative etiology. If hyperosmolar therapy is not initiated, do not perform a CT; continue to monitor neurological status for changes, including need for hyperosmolar therapy and CT.
- The use of standard preparation of tubing for insulin infusions in patients with DKA. (29-32) – Strong recommendation, low quality evidence
  Remarks: With equivocal evidence, the team felt that any additional time used to prepare could potentially delay treatment.
- The administration of lower-dose insulin infusions to children with DKA under the age of 5 and higher-dose insulin infusions to children aged 5 and older. (33-35) – Strong recommendation, low quality evidence
  Remarks: Though there is evidence that a lower-dose concentration of insulin is safe and effective, there is no evidence to suggest that the higher-dose concentration is harmful.

Evidence Lacking/Inconclusive

- Use of bicarbonate reported from the venous blood gas to guide the decision to start intravenous insulin therapy in patients whose bicarbonate values are <13 mmol/L; in patients whose bicarbonate levels are ≥13 mmol/L, wait for the laboratory values to confirm before initiating treatment. – Consensus recommendation
- To treat patients with diabetic ketoacidosis and hypokalemia with IV potassium. Consider oral supplementation after continuous intravenous insulin is discontinued and patient is able to tolerate oral medications. – Consensus recommendation
- To NOT decrease the insulin infusion if the blood glucose concentration decreases too quickly (greater than 100 mg/dL/hr) or falls too low (below 150 mg/dL) before DKA has resolved; rather, increase the amount of dextrose administered unless maximum already reached. Increase the amount of dextrose if patient is on less than 100% D10. – Consensus recommendation

*NOTE: The references cited represent the entire body of evidence reviewed to make each recommendation.

Condition-Specific Elements of Clinical Management

General: Children with DKA present with signs and symptoms that are related to the degree of hyperosmolality, volume depletion and acidosis. The severity of DKA should determine the appropriate clinical setting in which to treat the child.

Treatment Recommendations: For children being transferred from an outside hospital (OSH), please see Clinical Algorithm for Transport of Children with DKA on page 6.

Fluid and Electrolyte Therapy
Initiate fluid replacement therapy **BEFORE** insulin therapy. Normal saline should be administered at 20 mL/kg and if clinically indicated, repeat once. For subsequent fluids, administer 2.5 L/m^2/DAY and never exceed 4 L/m^2/DAY (including the initial bolus), unless discussed with Attending Physician.

Insulin Therapy
For all children who have a pH <7.3 an insulin infusion should be administered. The decision to administer subcutaneous insulin should be made in consideration of the child's hydration status.
Insulin Infusion- Administer continuous low dose IV infusions. Mix regular insulin, 100 units in 100 mL of Normal Saline (1 mL/h = 1 unit/h). Dose at 0.1 units/kg/h.
Maintain glucose between 100-200 mg/dL by titrating Bag A and Bag B. See Table 1.

Subcutaneous Insulin- Administer insulin as determined by Diabetes Service.

Phosphate
Administration of phosphate bolus is not routinely recommended.

Bicarbonate
Administration of bicarbonate is not recommended**.**

Potassium (K^+)
Potassium replacement is required if K^+ is ≤5.5. See Table I.

Table I. 2 Bag System

‡2 bag system		
If K^+ ≤5.5 mEq/L: (Adjust IVF rates based on finger stick glucoses)		
• Bag A: LR + KCl 1.5 mEq/100 mL+ KPO_4 2 mmol/100 mL		
• Bag B: D10LR + KCl 1.5 mEq/100 mL+ KPO_4 2 mmol/100 mL		
If K^+ >5.5 mEq/L: (Adjust IVF rates based on fingerstick glucoses)		
• Bag A: **LR**		
• Bag B: **D10LR**		
Total IVF mL/h = Bag A mL/h + Bag B mL/h		
Blood Glucose	**A**	**B**
>300 mg/dL	___ mL/h (100%)	0 mL/h
251-300 mg/dL	___ mL/h (75%)	___ mL/h (25%)
201-250 mg/dL	___ mL/h (50%)	___ mL/h (50%)
151-200 mg/dL	___ mL/h (25%)	___ mL/h (75%)
≤150 mg/dL	0 mL/h	___ mL/h (100%)
If <100 mg/dL	Notify practitioner while on IV therapy	

NOTE: The goal is to obtain a blood glucose of 150 mg/dL. However, if rate of drop is ≥100 mg/dL or if the patient becomes hypoglycemic, please consult Diabetes Team for reconsideration of fluid rate or type.

Special Care Monitoring
Blood glucose every 1 h
Chem 10 every 12 h
Electrolytes every 2 h x 3, then every 6 h with improving anion gap (Normal anion gap <15)
Strict I&O
β-hydroxybutyrate every 6 h

Cerebral Edema
Consider administering mannitol at 0.5 grams/kg or hypertonic saline (3%), and restricting fluids. If mannitol given and patient stable, consider computed tomography (CT) scan.

Medical Center Diabetes Care Unit Admission Criteria
- Children who have mild or moderate DKA (pH 7.0 - 7.30)
- Age 5 years and older

Medical Center Intensive Care Unit Admission Criteria
All children with one or more of the indicators below:
- Severe DKA (pH <7.0)
- Aged <5 years in DKA
- Altered mental status (AMS)
- >40 mL/kg of volume resuscitation
- Treatment with HCO_3
- Associated with sepsis/systemic inflammatory response syndrome (SIRS)

Community Facilities (West Campus/Woodlands/Austin) Intensive Care Unit Admission Criteria
- All patients with DKA on an insulin drip

Discharge Criteria
- Transition to subcutaneous insulin
- All education and social needs completed

Consults/Referrals/Follow-up Care
Consultation and follow up with a Diabetes specialist is appropriate for all children with diabetes.
Consultation with Psychology, Registered Dietician, Social Work, and Child Life for children with new onset or as determined by Endocrine.

Measures
Process
- Medical length of stay in Critical Care
- Medical length of stay in Diabetes Care Unit or Transitional Care Unit
- Total hospital medical length of stay
- # readmissions within one week of discharge

Outcome
- Time to administer subcutaneous insulin
- Incidence of cerebral edema after beginning therapy
- Time to correction of acidosis (e.g., normal anion gap <15; β-hydroxybutyrate <2; HCO_3 >15)
- pH level on arrival
- Glucose on arrival
- GCS on arrival
- # deaths with DKA diagnosis

Texas Children's Hospital Evidence-Based Outcomes Center
Clinical Algorithm for Initial Assessment of Diabetic Ketoacidosis (DKA)

For patients being transferred from outside hospital (OSH), see Clinical Algorithm for Transport of Children with DKA.

Inclusion Criteria: 6 months to 21 years; clinical findings of DKA.
Exclusion Criteria: 0 - 5 months of age; hyperglycemia without acidosis; pregnancy.

Initial history/clinical findings suggestive of DKA

Evidence of shock^
- Yes → - Place O_2
  - Administer normal saline 20 mL/kg bolus (repeat as needed)
  - Shock resolved
    - No → **OFF algorithm** Manage as appropriate to clinical findings
    - Yes
- No

Risk Factors for Cerebral Edema
- Age < 5 years
- New onset diabetes
- Use of HCO_3
- Low initial $PaCO_2$
- High initial serum BUN
- Rapid administration of hypotonic fluids
- Failure of corrected serum sodium to rise during treatment

NOTE: CE typically occurs 4-12 h after treatment is activated; however, it can be present before treatment has begun.

Evidence of Cerebral Edema? (Altered sensorium, headache, inappropriate slowing of the pulse rate, OR increase in BP)
- Yes →
  - Room immediately
  - Place O_2
  - Obtain or calculate serum osmolality
  - Consider mannitol 0.5 grams/kg or hypertonic saline (3%)
  - Consider restriction of fluids
  - If mannitol given and patient stable, consider CT scan

Obtain POC Beta Ketones

Whole Blood POC β Ketones ≥ 2.5 mmol/L
- No →
  LOW RISK of DKA
  - Room patient per routine
  - Ask if long acting insulin has been administered in last 12-24 hours or patient is on insulin pump
  - Send routine DM labs: HbA1C, BHBA, Chem 10, POC Venous Blood Gas with metabolites
  - Page Diabetes On Call Physician if new onset DM or if blood glucose > 250 mg/dL to order insulin in Epic or assist EC provider in order entry
- Yes →
  SUSPECTED DKA
  - Room patient as soon as possible
  - Administer normal saline 20 mL/kg bolus unless contraindicated (i.e., evidence of cerebral edema)
  - Obtain and send STAT lab: HbA1C, POC venous blood gas with metabolites, BHBA, Chem 10

pH < 7.3 and/or bicarbonate <15 mmol/L ?
- No → Update Diabetes On Call Physician on lab results & Dispo per ER
- Yes → Confirmed Diagnosis of DKA Reter to "Continuing Treatment for DKA" Algorithm (link)

For children with blood glucose of ≥ 800 mg/dL, hyperosmolar ketosis should be considered.

Clinical standards are developed for 80% of the patient population with a particular disease. Each practitioner must use his/her clinical judgment in the management of any specific patient

Texas Children's Hospital Evidence-Based Outcomes Center
Clinical Algorithm for Continuing Treatment of Diabetic Ketoacidosis

DKA confirmed

Inclusion Criteria: 6 months to 21 years; clinical findings of DKA.
Exclusion Criteria: 0 -5 months of age; Hyperglycemia without acidosis; pregnancy.

If patient is a candidate for DCU at Medical Center, contact Diabetes for initial recommendation. If patient admitted is admitted to DCU, contact PHM for admission orders. For all other DKAs, admit to PICU

MAIN CAMPUS

Admission Criteria to DCU
DCU – pH 7.0–7.3
Age 5 years and older

Admission Criteria to Intensive Care
Severe DKA with pH < 7.0
Age < 5y
Altered mental status
DKA and received more than 40mL/kg of fluid
Sepsis / SIRS
$NaHCO_3$ treatment

WEST CAMPUS/WOODLANDS/AUSTIN

Admission Criteria to Intensive Care
All patients with DKA on an insulin drip

***Risk Factors for Cerebral Edema (CE)**
- Age < 5 years
- New onset diabetes
- High initial serum BUN
- Low initial pCO_2
- Rapid administration of hypotonic fluids
- Failure of corrected serum sodium to rise during treatment
- Use of bicarbonate

Clinical Signs of CE
- Altered sensorium, headache
- Inappropriate slowing of the pulse rate
- Increase in BP

NOTE: CE typically occurs 4-12 h after treatment is activated; however, it can be present before treatment has begun.

Treatment
- Initiate 2 bag system‡
- Administer insulin infusion (0.1 units/kg/h if ≥ 5 years old, 0.05 units/kg/hr if < 5 years)
- *Replace potassium and phosphorus as needed*

Monitoring
- Continuous pulse oximetry and cardiac monitoring
- Neurological vital signs per unit policy
- POC Glucose q 1 h
- Chem 10 every 12 h
- Electrolytes every 2 h x 3, then every 6 h with improving anion gap (Normal anion gap < 15 mEq/L)
- ß-hydroxybutyrate every 6 h
- Strict I&O

Worsening labs; changes in mental status; **AND/OR** concerning vital signs

No

- Continue to manage as appropriate to clinical findings
- Contact Diabetes On Call Physician with changes in patient's status AND/OR recommendations for subcutaneous insulin dosing

Yes

- Consider transferring to higher level of care if in DCU
- Update Diabetes On Call Physician with changes in patient's status

‡2 bag system

If K^+ ≤ 5.5 mEq/L: (Adjust IVF rates based on finger stick glucoses)
- Bag A: LR + KCl 1.5 mEq/100 mL+ KPO_4 2 mmol/100 mL
- Bag B: D10LR + KCl 1.5 mEq/100 mL+ KPO_4 2 mmol/100 mL

If K^+ > 5.5 mEq/L : (Adjust IVF rates based on fingerstick glucoses)
- Bag A: **LR**
- Bag B: **D10LR**

Total IVF mL/h = Bag A mL/h + Bag B mL/h

blood glucose	**A**	**B**
> 300 mg/dL	___ mL/h (100%)	0 mL/h
251-300 mg/dL	___ mL/h (75%)	___ mL/h (25%)
201-250 mg/dL	___ mL/h (50%)	___ mL/h (50%)
151-200 mg/dL	___ mL/h (25%)	___ mL/h (75%)
≤ 150 mg/dL	0 mL/h	___ mL/h (100%)
If < 100 mg/dL	Notify practitioner while on IV therapy	

Texas Children's Hospital Evidence-Based Outcomes Center
Clinical Algorithm for Transport of Children with DKA



Clinical standards are developed for 80% of the patient population with a particular disease. Each practitioner must use his/her clinical judgment in the management of any specific patient.

References

1. Dunger, D. B., Sperling, M. A., Acerini, C. L., Bohn, D. J., Daneman, D., Danne, T. P. A., ... & Wolfsdorf, J. (2004). ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. *Archives of Disease in Childhood, 89*(2), 188-194.
2. Wolfsdorf, J., Glaser, N., & Sperling, M. (2006). Diabetic ketoacidosis in infants, children, and adolescents. *Diabetes Care*, 29(5), 1150-1159.
3. Pinkney, J. H., Bingley, P. J., Sawtell, P. A., Dunger, D. B., & Gale, E. A. (1994). Presentation and progress of childhood diabetes mellitus: A prospective population-based study. *Diabetologia, 37*(1), 70-74.
4. Dahlquist, G., & Kallen, B. (2005). Mortality in childhood-onset type 1 diabetes: A population based study. *Diabetes Care, 28*(10), 2384-2387.
5. Edge, J. A., Ford-Adams, M. E., & Dunger, D. B. (1999). Causes of death in children with insulin-dependent diabetes 1990-96. *Archives of Disease in Childhood, 81*(4), 318-323.
6. Edge, J. A., Jakes, R. W., Roy, Y., Hawkins, M., Winter, D., Ford-Adams, M. E., ... & Dunger, D. B. (2006). The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. *Diabetologia, 49*(9), 2002-2009.
7. Edge, J. A., Hawkins, M. M., Winter, D. L., & Dunger, D. B. (2001). The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. *Archives of Disease in Childhood, 85*(1), 16-22.
8. Glaser, N., Barnett, P., McCaslin, I., Nelson, D., Trainor, J., Louie, J., … & the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. (2001). Risk factors for cerebral edema in children with diabetic ketoacidosis. *New England Journal of Medicine, 344*(4), 264-269.
9. Hoorn, E. J., Carlotti, A. P., Costa, L. A., MacMahon, B., Bohn, G., Zietse, R., ... & Bohn, D. (2007). Preventing a drop in effective plasma osmolality to minimize the likelihood of cerebral edema during treatment of children with diabetic ketoacidosis. *Journal of Pediatrics, 150*(5), 467-473.
10. Lawrence, S. E., Cummings, E. A., Gaboury, I., & Daneman, D. (2005). Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. *Journal of Pediatrics, 146*(5), 688-692.
11. Marcin, J. P., Glaser, N., Barnett, P., McCaslin, I., Nelson, D., Trainor, J., ... & American Academy of Pediatrics: The Pediatric Emergency Medicine Collaborative Research Committee. (2002). Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. *Journal of Pediatrics, 141*(6), 793-797.
12. Umpierrez, G. E., Davis, G. M., El Sayed, N. A., Fadini, G. P., Galindo, R. J., Hirsch, I. B., ... & Dhatariya, K. K. (2024). Hyperglycemic crises in adults with diabetes: a consensus report. *Diabetes care*, *47*(8), 1257-1275.
13. Robles, F. C., Laguna Neto, D., Dias, F. G., Spressao, M., Matos, P. N., Cordeiro, J. A., & Pires, A. C. (2011). Diabetic ketoacidosis: Difference between potassium determined by blood gas analysis versus plasma measurement. *Arquivos Brasileiros de Endocrinologia e Metabologia, 55*(4), 256-259.
14. Bakes, K., Haukoos, J. S., Deakyne, S. J., Hopkins, E., Easter, J., McFann, K., ... & Rewers, A. (2016). Effect of volume of fluid resuscitation on metabolic normalization in children presenting in diabetic ketoacidosis: A randomized controlled trial. *Journal of Emergency Medicine, 50*(4), 551-559.
15. Basnet, S., Venepalli, P. K., Andoh, J., Verhulst, S., & Koirala, J. (2014). Effect of normal saline and half normal saline on serum electrolytes during recovery phase of diabetic ketoacidosis. *Journal of Intensive Care Medicine, 29*(1), 38-42.
16. Hsia, D. S., Tarai, S. G., Alimi, A., Coss-Bu, J. A., & Haymond, M. W. (2015). Fluid management in pediatric patients with DKA and rates of suspected clinical cerebral edema. *Pediatric Diabetes, 16*(5), 338-344.
17. Glaser, N. S., Tancredi, D. J., Marcin, J. P., Caltagirone, R., Lee, Y., Murphy, C., & Kuppermann, N. (2013). Cerebral hyperemia measured with near infrared spectroscopy during treatment of diabetic ketoacidosis in children. *Journal of Pediatrics, 163*(4), 1111-1116.
18. Glaser, N. S., Wootton-Gorges, S. L., Buonocore, M. H., Tancredi, D. J., Marcin, J. P., Caltagirone, R., ... & Kuppermann, N. (2013). Subclinical cerebral edema in children with diabetic ketoacidosis randomized to 2 different rehydration protocols. *Pediatrics, 131*(1), e73-80.
19. Kuppermann, N., Ghetti, S., Schunk, J. E., Stoner, M. J., Rewers, A., McManemy, J. K., ... & Glaser, N. S. (2018). Clinical trial of fluid infusion rates for pediatric diabetic ketoacidosis. *New England Journal of Medicine, 378*(24), 2275-2287.
20. Savas-Erdeve, S., Berberoglu, M., Oygar, P., Siklar, Z., Kendirli, T., Hacihamdioglu, B., ... & Ocal, G. (2011). Efficiency of fluid treatments with different sodium concentration in children with type 1 diabetic ketoacidosis. *Journal of Clinical Research in Pediatric Endocrinology, 3*(3), 149-153.
21. Toledo, J. D., Modesto, V., Peinador, M., Alvarez, P., Lopez-Prats, J. L., Sanchis, R., & Vento, M. (2009). Sodium concentration in rehydration fluids for children with ketoacidotic diabetes: Effect on serum sodium concentration. *Journal of Pediatrics, 154*(6), 895-900.
22. Yung, M., Letton, G., & Keeley, S. (2017). Controlled trial of Hartmann's solution versus 0.9% saline for diabetic ketoacidosis. *Journal of Paediatrics and Child Health, 53*(1), 12-17.
23. Cohen, M., Leibovitz, N., Shilo, S., Zuckerman-Levin, N., Shavit, I., & Shehadeh, N. (2017). Subcutaneous regular insulin for the treatment of diabetic ketoacidosis in children. *Pediatric Diabetes, 18*(4), 290-296.
24. Della Manna, T., Steinmetz, L., Campos, P. R., Farhat, S. C., Schvartsman, C., Kuperman, H., ... & Damiani, D. (2005). Subcutaneous use of a fast-acting insulin analog: An alternative treatment for pediatric patients with diabetic ketoacidosis. *Diabetes Care, 28*(8), 1856-1861.
25. Drop, S. L., Duval-Arnould, J. M., Gober, A. E., Hersh, J. H., McEnery, P. T., & Knowles, H. C. (1977). Low-dose intravenous insulin infusion versus subcutaneous insulin injection: A controlled comparative study of diabetic ketoacidosis. *Pediatrics, 59*(5), 733-738.
26. Edwards, G. A., Kohaut, E. C., Wehring, B., & Hill, L. L. (1977). Effectiveness of low-dose continuous intravenous insulin infusion in diabetic ketoacidosis. A prospective comparative study. *Journal of Pediatrics*, 91(5), 701-705.
27. Decourcey, D. D., Steil, G. M., Wypij, D., & Agus, M. S. (2013). Increasing use of hypertonic saline over mannitol in the treatment of symptomatic cerebral edema in pediatric diabetic ketoacidosis: An 11-year retrospective analysis of mortality*. *Pediatric Critical Care Medicine, 14*(7), 694-700.
28. Soto-Rivera, C. L., Asaro, L. A., Agus, M. S., & DeCourcey, D. D. (2017). Suspected cerebral edema in diabetic ketoacidosis: Is there still a role for head CT in treatment decisions? *Pediatric Critical Care Medicine, 18*(3), 207-212.
29. Fuloria, M., Friedberg, M. A., DuRant, R. H., & Aschner, J. L. (1998). Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. *Pediatrics, 102*(6), 1401-1406.
30. Hewson, M., Nawadra, V., Oliver, J., Odgers, C., Plummer, J., & Simmer, K. (2000). Insulin infusions in the neonatal unit: Delivery variation due to adsorption. *Journal of Paediatrics and Child Health, 36*(3), 216-220.
31. Simeon, P. S., Geffner, M. E., Levin, S. R., & Lindsey, A. M. (1994). Continuous insulin infusions in neonates: Pharmacologic availability of insulin in intravenous solutions. *Journal of Pediatrics, 124*(5 Pt 1), 818-820.
32. Thompson, C. D., Vital-Carona, J., & Faustino, E. V. (2012). The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. *Diabetes Technology and Therapeutics, 14*(10), 912-916.
33. Burghen, G. A., Etteldorf, J. N., Fisher, J. N., & Kitabchi, A. Q. (1980). Comparison of high-dose and low-dose insulin by continuous intravenous infusion in the treatment of diabetic ketoacidosis in children. *Diabetes Care*, *3*(1), 15-20.
34. Nallasamy, K., Jayashree, M., Singhi, S., & Bansal, A. (2014). Low-dose vs standard-dose insulin in pediatric diabetic ketoacidosis: A randomized clinical trial. *JAMA Pediatrics, 168*(11), 999-1005.
35. Puttha, R., Cooke, D., Subbarayan, A., Odeka, E., Ariyawansa, I., Bone, M., ... & Amin, R. (2010). Low dose (0.05 units/kg/h) is comparable with standard dose (0.1 units/kg/h) intravenous insulin infusion for the initial treatment of diabetic ketoacidosis in children with type 1 diabetes-an observational study. *Pediatric Diabetes, 11*(1), 12-17.

36. Bergmann, K. R., Abuzzahab, M. J., Nowak, J., Arms, J., Cutler, G., Christensen, E., ... & Kharbanda, A. (2021). Resuscitation with ringer's lactate compared with normal saline for pediatric diabetic ketoacidosis. *Pediatric Emergency Care*, *37*(5), e236-e242.
37. Liu, Y., Zhang, J., Xu, X., & Zou, X. (2024). Comparison of balanced crystalloids versus normal saline in patients with diabetic ketoacidosis: a meta-analysis of randomized controlled trials. *Frontiers in Endocrinology*, *15*, 1367916
38. Singhal, D., Gupta, S., & Kumar, V. (2024). Normal saline versus ringer's lactate for intravenous fluid therapy in children with diabetic ketoacidosis: A randomized controlled trial. *Indian Journal of Pediatrics*, 1-7.
39. Yıldırımçakar, D., Öcal, M., Altıncık, S. A., & Özhan, B. (2023). Hyperchloremia and Prolonged Acidosis During Treatment for Pediatric Diabetic Ketoacidosis. *Pediatric Emergency Care*, 10-1097.
40. Glaser, N., Fritsch, M., Priyambada, L., Rewers, A., Cherubini, V., Estrada, S., ... & Codner, E. (2022). ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. *Pediatric diabetes*, *23*(7).

Clinical Standards Preparation

This clinical standard was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children's Hospital. Development of this clinical standard supports the TCH Quality and Patient Safety Program initiative to promote clinical standards and outcomes that build a culture of quality and safety within the organization.

DIABETIC KETOACIDOSIS (DKA) Content Expert Team

Angela Baldonado, RN, Nursing
Rebecca Butler, Social Work
Kate DAmbrosio, RN, Nursing
Jaylon Daniels, RN, Nursing
Andrea DeJesus Martinez MD, Emergency Medicine
Sridevi Devaraj, MD, Pathology
Nicole Dumas, RN, Nursing
Zachary Foughty, MD, Emergency Medicine
Jeanine Graf, MD, Critical Care
Melanie Kitagawa, MD, Critical Care
Elizabeth Kubota-Mishra, MD, Endocrinology
Sarah Lyons, MD, Endocrinology
Saamia Masoom, MD, Emergency Medicine
Siripoom McKay, MD, Endocrinology
Julie McManemy MD, Emergency Medicine
Nelly Miranda, Diabetes Education
Matthew Musick, MD, Critical Care
Katherine Noldt, RN, Nursing
Tracy Patel, MD, Endocrinology
Matthew Pesek, MD, Critical Care
Natalie Pham, RN, Nursing
Paola Rondon Lira, RD, Nutrition
Rona Sonabend, MD, Endocrinology
Mustafa Tosur, MD, Endocrinology
Cheryl Trumble-Wilkins, RN, Nursing
EBOC Team

The following financial and/or intellectual conflict(s) was identified and addressed to ensure objectivity: Sarah Lyons - honorarium for physician consultant for online CME module; Royalty payments for book chapters; Member of national guideline writing committee; Member of Epic's national Pediatric Endocrinology Steering Board

Development Process

This clinical standard was developed using the process outlined in the EBOC Manual. The literature appraisal documents the following steps:

1. Review Preparation
   - PICO questions established
   - Evidence search confirmed with content experts

2. Review of Existing External Guidelines
   - American Diabetes Association "Standards of Medical Care in Diabetes"
   - ISPAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state
   - National Institute of Clinical Excellence "Diabetes (type 1 and type 2) in children and young people: diagnosis and management'
   - Ministry of Health, Social Services and Equality (Spain) "Clinical Practice Guideline for Diabetes Mellitus Type 1"

3. Literature Review of Relevant Evidence
   - Searched: Cochrane, PubMed

4. Critically Analyze the Evidence
   - 1 meta-analysis, 10 randomized controlled trials, and 15 nonrandomized studies

5. Summarize the Evidence
   - Materials used in the development of the clinical standard, literature appraisal, and any order sets are maintained in Diabetic Ketoacidosis (DKA) evidence-based review manual within EBOC.

Evaluating the Quality of the Evidence

Published clinical guidelines were evaluated for this review using the **AGREE II** criteria. The summary of these guidelines are included in the literature appraisal. AGREE II criteria evaluate Guideline Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity and Presentation, Applicability, and Editorial Independence using a 4-point Likert scale. The higher the score, the more comprehensive the guideline.

This clinical standard specifically summarizes the evidence *in support of* or *against* specific interventions and identifies where evidence is *lacking/inconclusive*. The following categories describe how research findings provide support for treatment interventions.

"Evidence Supports" provides evidence to support an intervention
"Evidence Against" provides evidence against an intervention.
"Evidence Lacking/Inconclusive" indicates there is insufficient evidence to support or refute an intervention and no conclusion can be drawn *from the evidence.*

The **GRADE** criteria were utilized to evaluate the body of evidence used to make practice recommendations. The table below defines how the quality of the evidence is rated and how a strong versus weak recommendation is established. The literature appraisal reflects the critical points of evidence.

Recommendation	
STRONG	Desirable effects clearly outweigh undesirable effects or vice versa
WEAK	Desirable effects closely balanced with undesirable effects
Quality	**Type of Evidence**
High	Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies
Moderate	Evidence from RCTs with important limitations (e.g., inconsistent results, methodological flaws, indirect evidence, or imprecise results) or unusually strong evidence from unbiased observational studies
Low	Evidence for at least 1 critical outcome from observational studies, RCTs with serious flaws or indirect evidence
Very Low	Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence

Recommendations

Practice recommendations were directed by the existing evidence and consensus amongst the content experts. Patient and family preferences were included when possible. The Content Expert Team and EBOC team remain aware of the controversies in the diagnosis/management of Diabetic Ketoacidosis (DKA) in children. When evidence is lacking, options in care are provided in the clinical standard and the accompanying order sets (if applicable).

Approval Process

Clinical standards are reviewed and approved by hospital committees as deemed appropriate for its intended use. Clinical standards are reviewed as necessary within EBOC at Texas Children's Hospital. Content experts are involved with every review and update.

Disclaimer

Practice recommendations are based upon the evidence available at the time the clinical standard was developed. Clinical standards (guidelines, summaries, or pathways) do not set out the standard of care and are not intended to be used to dictate a course of care. Each physician/practitioner should use his or her independent judgment in the management of any specific patient and is responsible, in consultation with the patient and/or the patient's family, to make the ultimate judgment regarding care.

Permission of Use

Version History

Date	Comments
Nov 2009	Originally completed
Oct 2014	Algorithm modifications
Jan 2015	Algorithm modifications
Mar 2015	Algorithm modifications
Jun 2015	Algorithm modifications
May 2019	Updated
May 2020	Changed the recommendation for hyperchloremic acidosis
Jun 2020	Changed the recommendation for cerebral edema. Algorithm updates to reflect the change.
Sept 2021	Revision to Transport Algorithm
Jun 2025	PICO questions reviewed, literature review updated for maintenance fluids, updated algorithms